Date published 
October 2012

 

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR Bundle

Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations - Tables and Figures

 

Author: Lucy J. Sannes, PhD, MBA 

TABLESTable 2.1. Incidence and Mortality of Selected Solid Tumors in the United States, 2011
Table 2.2. Five-Year Relative Survival Rates by Stage of Diagnosis (1999–2006) For Selected Major Cancers Targeted by Pharmaceutical Companies
Table 3.1. Selected Chemotherapy Drugs FDA-Approved for Treatment of Cancer (Most Are Available as Generic Drugs)
Table 3.2. Selected Drugs Approved By the FDA for Treatment of Brain Cancer
Table 3.3. Selected Drugs Approved By the FDA for Treatment of Breast Cancer
Table 3.4. Selected Drugs Approved By the FDA for Treatment of Cervical Cancer
Table 3.5. Selected Drugs Approved By the FDA for Treatment of Colorectal Cancer
Table 3.6. Selected Drugs Approved By the FDA for Treatment of Head & Neck Cancer
Table 3.7. Selected Drugs Approved By the FDA for Treatment of Non–Small-Cell Lung Cancer
Table 3.8. Selected Drugs Approved By the FDA for Treatment of Small-Cell Lung Cancer
Table 3.9. Selected Drugs Approved By the FDA for Treatment of Melanoma
Table 3.10. Selected Drugs Approved By the FDA for Treatment of Ovarian Cancer
Table 3.11. Selected Drugs Approved By the FDA for Treatment of Pancreatic Cancer
Table 3.12. Selected Drugs Approved By the FDA for Treatment of Prostate Cancer
Table 3.13. Selected Drugs Approved By the FDA for Treatment of Renal Cancer
Table 3.14. Selected Drugs Approved By the FDA for Treatment of Other Solid Tumors
Table 4.1. Selected Inhibitors of EGF Receptor Tyrosine Kinase Family
Table 4.2. Selected Inhibitors of the Ras-Raf-MEK-ERK Pathway
Table 4.3. Selected Inhibitors of c-Met
Table 4.4. Selected Inhibitors of Insulin-Like Growth Factor (IGF) and Insulin-Like Growth Factor Type 1 Receptor (IGF1R)
Table 4.5. Selected TGF-β2 Inhibitors
Table 4.6. Selected c-Kit Inhibitors
Table 4.7. Selected PARP (Poly [ADP-Ribose] Polymerase) Inhibitors
Table 4.8. Selected Inhibitors of the PI3K-Akt-mTOR Pathway
Table 4.9. Selected Other Emerging Therapies with Antiproliferative Effects
Table 5.1. Selected Emerging Therapies That Induce Apoptosis
Table 6.1. Selected Growth Factor Receptors and Their Ligands Involved in Angiogenesis
Table 6.2. Selected Angiogenesis Inhibitors That Target VEGFR, PDGFR, or FGFR
Table 6.3. Selected Angiogenesis Inhibitors That Target TIE Receptor and/or Its Ligands
Table 6.4. Selected Integrin Inhibitors
Table 6.5. Selected Other Angiogenesis Inhibitors
Table 6.6. Selected Vascular-Targeting/Disrupting Agents
Table 7.1. Selected Emerging Therapies with Anti-Androgen Activity
Table 7.2. Selected Other Emerging Therapies Targeting Regulation of Hormones
Table 8.1. Selected Emerging Immunotherapies, Immunomodulators, and Vaccines for Treatment of Cancer
Table 8.2. Selected Emerging Immunoconjugates for Treatment of Cancer
Table 9.1. Selected Emerging Cytotoxic Drugs in Development for Treatment of Cancer
Table 10.1. Selected Other Emerging Therapies for Solid Tumors
Table 11.1. Sales of Selected Drugs Used to Treat Solid Tumors